10-Q: Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results, Highlights Progress in Cell Therapy Programs

Lineage Cell Therapeutics announces its financial results for the first quarter of 2025, showcasing advancements in its allogeneic cell therapy programs for neurological and ophthalmic conditions.

Summary

• Lineage Cell Therapeutics reported a net loss attributable to Lineage of $4.139 million, or $0.02 per share, for the three months ended March 31, 2025.
• This compares to a net loss of $6.542 million, or $0.04 per share, for the same period in 2024.
• The company's cash, cash equivalents, and marketable securities totaled $47.9 million as of March 31, 2025.
• Revenues for the quarter were $1.502 million, up from $1.444 million in the prior year.
• Research and development expenses increased slightly to $3.114 million from $3.010 million.
• General and administrative expenses decreased to $4.857 million from $4.997 million.
• The DOSED clinical study, evaluating a novel spinal cord delivery device for OPC1, is expected to commence enrollment in June 2025.
• The company believes its current cash resources will be sufficient to fund planned operations for at least twelve months from the issuance date of the financial statements.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is still operating at a loss, there are improvements in revenue and a decrease in net loss compared to the previous year. The progress in clinical trials and the belief that current cash resources are sufficient for the next twelve months are also positive indicators. However, the risks associated with the Israeli regional conflict and macroeconomic conditions temper the overall sentiment.

Positives

• Revenues increased to $1.502 million for the quarter, up from $1.444 million in the prior year, driven by collaboration revenues from the Roche Agreement.
• General and administrative expenses decreased to $4.857 million from $4.997 million.
• The DOSED clinical study, evaluating a novel spinal cord delivery device for OPC1, is expected to commence enrollment in June 2025.
• The company believes its current cash resources will be sufficient to fund planned operations for at least twelve months.

Negatives

• Lineage Cell Therapeutics reported a net loss attributable to Lineage of $4.139 million for the three months ended March 31, 2025.
• The company has an accumulated deficit of $407.6 million as of March 31, 2025.
• The company expects to continue to incur significant operating losses for the foreseeable future.

Risks

• The company's operations could be materially and adversely impacted by the Israeli regional conflict and broader regional conflict.
• The company's business, financial condition, operating results, stock price, and ability to raise additional capital may be adversely affected by evolving macroeconomic, political, and regulatory developments and conditions.
• The company may be unable to consistently manufacture clinical quantities of its product candidates in accordance with cGMP from a master and working cell bank system, or at a cost-effective or commercially viable scale.

Future Outlook

Lineage believes its current cash resources will be sufficient to fund planned operations for at least twelve months from the issuance date of the financial statements and expects to continue to incur losses for at least the next several years.

Industry Context

Lineage is operating in the competitive cell therapy space, focusing on allogeneic 'off-the-shelf' therapies. The company's collaboration with Roche and Genentech for OpRegen places it alongside other companies developing treatments for age-related macular degeneration and other ophthalmic disorders. The initiation of the DOSED study for OPC1 positions Lineage in the spinal cord injury treatment market, where there is a significant unmet need for therapies that improve functional outcomes.

Comparison to Industry Standards

• Lineage's collaboration with Roche for OpRegen is similar to other partnerships in the biotech industry, such as the collaboration between BioNTech and Genentech to develop mRNA cancer immunotherapies.
• The $50 million upfront payment received by Lineage from Roche is comparable to upfront payments in other licensing agreements in the cell therapy and regenerative medicine fields.
• Lineage's focus on allogeneic cell therapies aligns with a broader industry trend towards developing scalable and cost-effective cell-based treatments, as opposed to autologous therapies that are patient-specific and more complex to manufacture.
• The company's efforts to establish a reproducible and scalable cGMP cell therapy production capability are critical for competing with companies like Vertex, which is also working on cell therapies at scale.

Legal Proceedings

• CCN received a motion for disclosure of documents pursuant to Section 198A of the Israeli Companies Law 5759-1999 from HBL Hadasit Bio-Holdings Ltd. (HBL), currently an approximately 5% shareholder of CCN.

Related Party Transactions

• In January 2025, Broadwood Partners purchased 7,894,737 common shares and an accompanying warrant to purchase up to 7,894,737 common shares from us in the November 2024 RDO.

Stakeholder Impact

• Shareholders: The report provides information on the company's financial performance and progress in clinical trials, which can influence investment decisions.
• Employees: The report highlights the company's ongoing operations and future plans, which can impact employee morale and job security.
• Customers/Partners: The report provides updates on the development of the company's product candidates, which can impact potential collaborations and licensing agreements.
• Creditors: The report provides information on the company's financial condition and ability to meet its obligations.

Next Steps

• Commence enrollment in the DOSED clinical study in June 2025.
• Continue development of OpRegen in collaboration with Roche and Genentech.
• Apply for additional funding from CIRM to support continued clinical development of OPC1 for the treatment of SCI.
• Continue to monitor and manage the impact of the Israeli regional conflict on operations.

Key Dates

Keywords

cell therapy, OpRegen, OPC1, clinical trial, financial results, Lineage Cell Therapeutics, allogeneic, neurological, ophthalmic, DOSED study, Roche Agreement